Targeting oncogenic KRAS in non-small cell lung cancer with EGFR aptamer-conjugated multifunctional RNA nanoparticles

KRAS mutations are one of the most common oncogenic driver mutations in human cancers, including non-small cell lung cancer (NSCLC), and have established roles in cancer pathogenesis and therapeutic resistance. The development of effective inhibitors of mutant KRAS represents a significant challenge...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Linlin, Li, Zhefeng, Binzel, Daniel W., Guo, Peixuan, Williams, Terence M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10448464/
https://www.ncbi.nlm.nih.gov/pubmed/37637206
http://dx.doi.org/10.1016/j.omtn.2023.07.027

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10448464/
https://www.ncbi.nlm.nih.gov/pubmed/37637206
http://dx.doi.org/10.1016/j.omtn.2023.07.027

Ejemplares similares